This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BAX vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. LMAT: Which Stock Is the Better Value Option?
SRDX Stock Down Despite FDA Clearance for Pounce XL System
by Zacks Equity Research
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
Are Investors Undervaluing Baxter International (BAX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
by Zacks Equity Research
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
by Zacks Equity Research
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
VEEV Stock Down Despite Expansion of Vault QMS to Boost Patient Safety
by Zacks Equity Research
Veeva Systems' addition of new capabilities is likely to improve the timeliness and accuracy of field actions to ensure product quality and patient safety.
Zacks Industry Outlook Highlights Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health
by Zacks Equity Research
Boston Scientific, Baxter International, Haemonetics and Phibro Animal Health are part of the Zacks Industry Outlook article.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
4 Medical Product Stocks to Buy From a Prospective Industry
by Indrajit Bandyopadhyay
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout
by Zacks Equity Research
Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio Now
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.
MASI Stock Gains as US Court Raises Concern About Politan's Ethics
by Zacks Equity Research
Shares of Masimo have risen since the news of a court ruling against Politan. The ruling is likely to favor MASI's founder in the upcoming vote for new board members on Sept. 19.
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
Masimo's Stock Up Following the New Tie-Up With Google to Boost Wear OS
by Zacks Equity Research
MASI's latest partnership is likely to develop a new reference platform that brings high-performing Wear OS smartwatches to market.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
by Zacks Equity Research
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
Baxter (BAX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BAX vs. PODD: Which Stock Is the Better Value Option?
Is Baxter International (BAX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
by Zacks Equity Research
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Baxter (BAX) Q2 Earnings Beat Estimates, '24 EPS View Raised
by Zacks Equity Research
Baxter (BAX) reports better-than-expected second-quarter earnings and sales. Its quarterly results reflect solid demand for a range of its medically essential products.